Citation Impact
Citing Papers
Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor
1991 Standout
Parenteral Anticoagulants
2008
ORG 10172: a low molecular weight heparinoid anticoagulant with a long half‐life in man.
1987
Parenteral Anticoagulants
2012 Standout
Heparin-Protein Interactions
2002 Standout
Structure and Biological Activity of Heparin
1985
Molecular cloning and expression of a hexameric Drosophila heat shock factor subject to negative regulation
1990
Anticoagulant Use in Patients with Chronic Renal Impairment
2005
Prevention of Deep Vein Thrombosis after Elective Hip Surgery
1991
The Antithrombotic Activity and Pharmacokinetics of Enoxaparine, A Low Molecular Weight Heparin, In Humans Given Single Subcutaneous Doses of 20 to 80 mg
1988
Heparin and Low-Molecular-Weight Heparin Mechanisms of Action, Pharmacokinetics, Dosing, Monitoring, Efficacy, and Safety
2001 Standout
Immobilized metal ion affinity chromatography
1992
The Groucho/Transducin-like Enhancer of split Transcriptional Repressors Interact with the Genetically Defined Amino-terminal Silencing Domain of Histone H3
1997
Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia
1995
Metal-Affinity Separations: A New Dimension in Protein Processing
1991 StandoutNobel
Glycosylinositol Phospholipid Anchors of the Scrapie and Cellular Prion Proteins Contain Sialic Acid
1992 StandoutNobel
Regulation of the heat shock transcriptional response: cross talk between a family of heat shock factors, molecular chaperones, and negative regulators
1998 Standout
Subcutaneous Low-Molecular-Weight Heparin Compared with Continuous Intravenous Heparin in the Treatment of Proximal-Vein Thrombosis
1992 Standout
Celastrols as Inducers of the Heat Shock Response and Cytoprotection
2004 Standout
Temporal Aspects of Heparin-Induced Thrombocytopenia
2001 Standout
Isolation and characterization of heparan sulfate from crude porcine intestinal mucosal peptidoglycan heparin
1995
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
1996 Standout
Antithrombotic Therapy for VTE Disease
2012 Standout
Frequency of pulmonary embolism in patients who have iliofemoral deep vein thrombosis and are treated with once- or twice-daily low-molecular-weight heparin
1996
Heparin and Low-Molecular-Weight Heparin
2004
Mechanisms responsible for the failure of protamine
to inactivate low‐molecular‐weight heparin
2002
Phase transitions in the assembly of multivalent signalling proteins
2012 StandoutNature
The effect of molecular weight on heparin binding to platelets
1990
Prevention of Venous Thromboembolism
2004 Standout
Heparin and Low-Molecular-Weight Heparin
1998
The Hazards of Scoring the Quality of Clinical Trials for Meta-analysis
1999 Standout
Heparin-Induced Thrombocytopenia in Patients Treated with Low-Molecular-Weight Heparin or Unfractionated Heparin
1995 Standout
Clinical evaluation of low-molecular-weight heparin (FR-860) on disseminated intravascular coagulation (DIC) - a multicenter co-operative double-blind trial in comparison with heparin -
1993
The Multifunctional Fish Gill: Dominant Site of Gas Exchange, Osmoregulation, Acid-Base Regulation, and Excretion of Nitrogenous Waste
2004 Standout
Characterization of recombinant human .alpha.2-antiplasmin and of mutants obtained by site-directed mutagenesis of the reactive site
1987
Characterization of the heparin-binding site of glia-derived nexin/protease nexin-1
1992
Dose adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin
1990
Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: Results of a meta-analysis
1996
Disseminated Intravascular Coagulation
1999 Standout
Heparin
1991
A Comparison of Low-Molecular-Weight Heparin with Unfractionated Heparin for Unstable Coronary Artery Disease
1997 Standout
Interaction of factor Xa with heparin does not contribute to the inhibition of factor Xa by antithrombin III-heparin
1990
Stress-induced oligomerization and chromosomal relocalization of heat-shock factor
1991 Nature
Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis
1992
A Comparison of Enoxaparin with Placebo for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients
1999 Standout
Pharmacotherapeutic Aspects of Unfractionated and Low Molecular Weight Heparins
1990
Organic Azides: An Exploding Diversity of a Unique Class of Compounds
2005 Standout
Heparin inhibition of von Willebrand factor-dependent platelet function in vitro and in vivo.
1991
Recent observations on the role of hemostatic determinants in the development of the atherothrombotic plaque
1994
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
2011 Standout
Glycosaminoglycans and the regulation of blood coagulation
1993
Structure-activity relationship in heparin: A synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity
1983
The antithrombin-binding sequence of heparin. Location of essential N-sulfate groups.
1981
The Binding of Low-Affinity and High-Affinity Heparin to Antithrombin. Fluorescence Studies
1978
Purification of antithrombin III by affinity chromatography
1974
Extracellular DNA traps promote thrombosis
2010 Standout
Deficiency of protein C in congenital thrombotic disease.
1981 Standout
Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia
1994
Serpin Structure, Mechanism, and Function
2002 Standout
The effects of low molecular weight and standard heparin on calcium loss from fetal rat calvaria
1995
The saga of IMAC and MIT
1989
Binding of low-affinity and high-affinity heparin to antithrombin. Ultraviolet difference spectroscopy and circular dichroism studies
1978
Energetics and Dynamics of Enzymatic Reactions
2001 StandoutNobel
The relative contributions of antithrombin iii during heparin treatment, and of clinically recognisable risk factors, to early recurrence of venous thromboembolism.
1987
Characterization of monoclonal antibodies specific for the Lewis a human blood group determinant.
1983 StandoutNobel
Release of a Two‐Chain Form of Antithrombin from the Antithrombin‐Thrombin Complex
1979
The structure of heparin oligosaccharide fragments with high anti-(factor Xa) activity containing the minimal antithrombin III-binding sequence Chemical and13C nuclear-magnetic-resonance studies
1981
Kinetics of intravenously administered heparin in normal humans
1982
Exploring the Metabolic and Genetic Control of Gene Expression on a Genomic Scale
1997 StandoutScience
Neutralization of heparin by histone and its subfractions
1983
Aggregation-Induced Emission: Together We Shine, United We Soar!
2015 Standout
Low molecular weight heparin (PK 10169) does not cross the placenta during the second trimester of pregnancy study by direct fetal blood sampling under ultrasound
1984
Low molecular weight heparin
1992
Guide to anticoagulant therapy. Part 1: Heparin. American Heart Association.
1994
Treatment of acute venous thromboembolism with low molecular weight heparin (Fragmin). Results of a double-blind randomized study.
1989
Anticoagulant and antithrombotic effects of heparin and low molecular weight heparin fragments in rabbits
1982
The Size and Shape of Human and Bovine Antithrombin III
1977
Effect of Heparin and Heparin Fractions on Platelet Aggregation
1980
THE MAMMALIAN UNFOLDED PROTEIN RESPONSE
2005 Standout
Further characterization of the antithrombin-binding sequence in heparin
1982 Standout
Randomized trial of subcutaneous low-molecular-weight heparin CY 216 (Fraxiparine) compared with intravenous unfractionated heparin in the curative treatment of submassive pulmonary embolism. A dose-ranging study.
1992
Comparison of the Non-Specific Binding of Unfractionated Heparin and Low Molecular Weight Heparin (Enoxaparin) to Plasma Proteins
1993
Neutralization of heparin-related saccharides by histidine-rich glycoprotein and platelet factor 4.
1986
The antithrombin-binding sequence of heparin studied by n.m.r. spectroscopy
1981
Studies on the Mechanism of the Rate‐Enhancing Effect of Heparin on the Thrombin‐Antithrombin III Reaction
1979
Heparin cofactor II. Purification and properties of a heparin-dependent inhibitor of thrombin in human plasma.
1982
Partial NH2- and cooh-terminal sequence analyses of Eco RI DNA restriction and modification enzymes.
1981 StandoutNobel
The molecular-weight dependence of the rate-enhancing effect of heparin on the inhibition of thrombin, factor Xa, factor IXa, factor XIa, factor XIIa and kallikrein by antithrombin
1981
The Unique Antithrombin III Binding Domain of Heparin: A Lead to New Synthetic Antithrombotics
1993
A Randomized Double-Blind Study Between a Low Molecular Weight Heparin Kabi 2165 and Standard Heparin in the Prevention of Deep Vein Thrombosis in General Surgery
1988
A yeast ARS-binding protein activates transcription synergistically in combination with other weak activating factors.
1990 StandoutNobel
Interaction of single-chain urokinase-type plasminogen activator with human endothelial cells.
1990 StandoutNobel
New Biarsenical Ligands and Tetracysteine Motifs for Protein Labeling in Vitro and in Vivo: Synthesis and Biological Applications
2002 StandoutNobel
Evidence for a 3-O-sulfated D-glucosamine residue in the antithrombin-binding sequence of heparin.
1980
Activation of human heat shock genes is accompanied by oligomerization, modification, and rapid translocation of heat shock transcription factor HSF1.
1993
Heparin binding properties of human histidine-rich glycoprotein. Mechanism and role in the neutralization of heparin in plasma.
1983
Spontaneous missense mutation of an immunoglobulin in a mouse myeloma cell line
1977 StandoutNobel
Factor IX antigen by radioimmunoassay. Abnormal factor IX protein in patients on warfarin therapy and with hemophilia B.
1977
Comparison between commercial heparin, low molecular weight heparin and pentosan polysulfate on hemostasis and platelets in vivo
1982
Low molecular weight heparin once daily compared with conventional low-dose heparin twice daily. A prospective double-blind multicentre trial on prevention of postoperative thrombosis
1986
A yeast protein that influences the chromatin structure of UASG and functions as a powerful auxiliary gene activator.
1990 StandoutNobel
Heparin with two binding sites for antithrombin or platelet factor 4.
1982
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
2015 Standout
Coronary Plaque Disruption
1995 Standout
Low-Molecular-Weight Heparins
1997 Standout
Die charakteristische AT‐III‐Bindungsregion in Heparin: eine Leitstruktur für neue synthetische Antithrombotica
1993
Stimulation by heparin of the plasmin-mediated conversion of single-chain to two-chain urokinase-type plasminogen activator
1986
Preparation of highly stable antithrombin-sepharose and utilization for the fractionation of heparin
1982
Role of ternary complexes, in which heparin binds both antithrombin and proteinase, in the acceleration of the reactions between antithrombin and thrombin or factor Xa.
1986
The molecular size of the antithrombin‐binding sequence in heparin
1980
Notch Signaling: Cell Fate Control and Signal Integration in Development
1999 StandoutScience
Importance of Size, Sulfation, and Anticoagulant Activity in the Potentiation of Acidic Fibroblast Growth Factor by Heparin
1989
Low Molecular Weight Heparin and Compression Stockings in the Prevention of Venous Thromboembolism in Neurosurgery
1996
Structure of the antithrombin-binding site in heparin.
1979
Synthesis, processing, and secretion of recombinant human factor VIII expressed in mammalian cells.
1988
Comparison of amino acid sequence of bovine coagulation Factor IX (Christmas Factor) with that of other vitamin K-dependent plasma proteins.
1979
Activation of heat shock gene transcription by heat shock factor 1 involves oligomerization, acquisition of DNA-binding activity, and nuclear localization and can occur in the absence of stress.
1993
Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4
1984
The CYC8 and TUP1 proteins involved in glucose repression in Saccharomyces cerevisiae are associated in a protein complex.
1991
Functions of Cell Surface Heparan Sulfate Proteoglycans
1999 Standout
TUF, the yeast DNA-binding factor specific for UASrpg upstream activating sequences: identification of the protein and its DNA-binding domain.
1987
2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
2014 Standout
Isoelectric focusing in gels
1974
Extension and structural variability of the antithrombin-binding sequence in heparin.
1984
Catabolism of low-dose heparin in man
1979
Disappearance of circulating anti-Xa activity after intravenous injection of standard heparin and of a low molecular weight heparin (CY 216) in normal and nephrectomized rabbits
1985
Fluorescence-Based Blood Coagulation Assay Device for Measuring Activated Partial Thromboplastin Time
2010 StandoutNobel
Connections Between Transcriptional Activators, Silencers, and Telomeres as Revealed by Functional Analysis of a Yeast DNA-Binding Protein
1988 StandoutNobel
Argatroban Anticoagulant Therapy in Patients With Heparin-Induced Thrombocytopenia
2001 Standout
The molecular-weight-dependence of the anti-coagulant activity of heparin
1978
Purification, characterization, and bioassay of teleocalcin, a glycoprotein from salmon corpuscles of Stannius
1986
A Yeast ARS-Binding Protein Activates Transcription Synergistically in Combination with Other Weak Activating Factors
1990 StandoutNobel
cGMP-dependent protein kinase, a chimeric protein homologous with two separate protein families
1984 StandoutNobel
Low molecular weight heparin
1992
Anticoagulant effects of two types of low molecular weight heparin administered subcutaneously
1983
Spontaneous somatic frameshift mutation in a mouse myeloma
1978 StandoutNobel
Works of L.-O. Andersson being referenced
Molecular weight estimations of proteins by electrophoresis in polyacrylamide gels of graded porosity
1972
Anticoagulant properties of heparin fractionated by affinity chromatography on matrix-bound antithrombin III and by gel filtration
1976
Interaction of factor VIII-von Willebrand Factor with phospholipid vesicles
1981
Determination of platelet factor 3 in whole blood by a chromogenic peptide substrate assay
1980
Purification and characterization of human factor IX
1975
Anticoagulant activities and effects on platelets of a heparin fragment with high affinity for antithrombin
1980
Immobilized metal ion affinity chromatography of serum albumins.
1991
Elimination of high affinity heparin fractions and their anticoagulant and lipase activity
1984
Isolation and characterization of lipid-protein particles containing platelet factor 3 released from human platelets
1982
Properties of antithrombin III depleted plasma I. Effect of heparin
1980
Crossed immunoelectrophoresis as applied to studies on complex formation. The binding of heparin to antithrombin III and the antithrombin III-thrombin complex
1977
Molecular weight dependency of the heparin potentiated inhibition of thrombin and activated factor X. Effect of heparin neutralization in plasma
1979